RARECast

RARECast

By RARECastBusiness
Download on the App Store

RARECast episodes

  • A Controversial Approval for a Duchenne Drug and What's Ahead
    The controversial approval of Sarepta Therapeutics eteplirsen to treat a certain form of Duchenne muscular dystrophy has been viewed as a major victory for patient advocates. Advocates aggressively lobbied the U.S. Food and Drug Administration to grant approval for the drug despite a weak data package presented by the company. Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research overrode staff to greenlight the drug. We spoke to Debra Miller, president, CEO, and co-founder of CureDuchenne, about the significance of the approval, her organization’s venture philanthropy model, and what other hope the Duchenne drug pipeline may hold for patients.
    17 min
  • Matchmaker Exchange Helps Rare Disease Community Find Me a Find
    As databases containing the genetic information of individuals proliferate, an opportunity for physicians, researchers, and individual to find people with specific rare mutations exists. Matchmaker Exchange represents an effort to tie together a variety of databases and make them accessible through a single portal. We spoke to Anthony Philippakis, cardiologist at Brigham and Women’s Hospital and a data scientist at the Broad Institute’s Program for Medical and Population Genetics, about the Matchmaker Exchange, which he helped create. Philippakis discussed how the exchange works, the benefits he hopes it will provide, and the technical and other challenges it faces.
    17 min
  • The Promise of RNAi for Hereditary Angioedema and Other Rare Diseases
    Hereditary angioedema is a rare genetic disease that causes episodes of severe swelling. The swelling can occur in the limbs, face, intestinal tract and elsewhere. Sometimes, it can be life threatening if the swelling obstructs breathing. Though there are limited therapeutic options available, a class of drugs known as RNA interference is offering hope. We spoke to Marc Riedl, professor of medicine and clinical director of the US HAEA Angiodema Center at the University of California, San Diego, about hereditary angioedema, how RNA interference therapies work, and why this may be an area of promise for this and other rare diseases.
    18 min
  • Why Natural History Studies Matter to Rare Disease Patients
    Peroxisomal disorders are a group of rare and heterogeneous metabolic diseases. Earlier this year, the National Organization for Rare Disorders selected the Global Foundation for Peroxisomal Disorders as one of 20 rare disease groups to undertake a natural history study with support from the U.S. Food and Drug Administration. We spoke to Melissa Bryce Gamble, president and co-founder of the Global Foundation for Peroxisomal Disorders, about the natural history study, why such studies are critical for expanding the understanding of a rare disease, and how they help inform the development of therapies.
    19 min
  • Harnessing Big Data to Work for Rare Disease Patients
    The improved ability to generate and capture data is providing researchers with the potential for new insights into diseases, but the growing volume and complexity of the data has made it difficult to translate all of this into actionable information. We spoke to Spyros Mousses, founder and president of Systems Imagination, about the what the emerging world of Big Data means for rare disease patients, how it requires new ways of approaching scientific problems, and why innovative collaborations are becoming more important than ever to develop new therapies.
    25 min
  • Lessons from Autism on Accelerating Drug Development
    The genomic revolution promises to unlock the underlying mechanism of many rare diseases and disorders, but progress in translating new discoveries into therapies that benefit patients can be frustratingly slow. We spoke to Robert Ring, former chief scientific officer of Autism Speaks, about innovative efforts he’s been involved with to overcome bottlenecks in translational medicine, advance research, and attract investment into drug development.
    22 min
  • How One Rare Disease Group Leverages Relationships with Industry
    The International Fibrodysplasia Ossificans Progressiva Association focuses on a rare genetic disorder, but it has had great success in stimulating research, engaging with industry, and helping advance needed therapies. We spoke to Betsy Bogard, global research development director for the IFOPA, about FOP, how her organization has helped drive work toward new treatments, and what it’s learned about how to best work with industry partners.
    19 min
  • Ice Bucket Challenge Begins to Yield Results
    Two years ago, the ALS Association’s Ice Bucket Challenge became a viral sensation on the Internet and raised $115 million to fight the progressive neurodegenerative disease. Now those doused donors are seeing concrete results from the money they gave. A recent paper in Nature Genetics reported on the identification of a new gene that is a contributor to ALS, a finding that was funding in part from Ice Bucket Challenge money and could lead to new therapies. We spoke to Lucie Bruijn, chief scientist of the ALS Association, about the findings, their significance, and lessons for other disease groups seeking to accelerate research.
    18 min
  • Why a Common Diabetes Drug May Be Able to Treat a Rare Disease
    A widely used drug to treat diabetes may hold promise as a therapeutic for patients with Maple Syrup Urine Disease, a rare, inherited metabolic disorder involving the dysfunction of an enzyme needed to break down three essential amino acids. The findings, which appear in a new study in Nature Scientific Reports come from researchers at the Buck Institute for Research on Aging. We spoke to Arvind Ramanathan, senior author of the study and a member of the Buck faculty, about the study, what it says about the ability to understand more common diseases through the study of rare diseases, and how repurposing existing therapies holds promise of brining new treatments to rare disease patients who are without them.
    20 min
  • How to Improve Patient Access to Experimental Drugs
    Expanded access—a means by which physicians and patients can obtain experimental drugs outside of a clinical trial—has been an area of growing interest among rare disease patients. Jess Rabourn, co-founder and managing director of WideTrial, in a new white paper addresses some common misconceptions about expanded access and argues for a new model that aligns charitable, scientific and medical interests for wider patient engagement. We spoke to Rabourn about the evolution of the concept of expanded access, why commercial viability and not the FDA has been the biggest obstacle, and how public-private partnerships can greatly expand their use.
    27 min

About RARECast

From the publisher's feed

RARECast is a Global Genes podcast hosted by award-winning journalist Daniel Levine. It focuses on the intersection of rare disease with business, science, and policy.